Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 6/20 | 0.40 |
| ▸ | KDR | P35968 | 11/20 | 0.39 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 2/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | CIT | O14578 | 1/20 | 0.38 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.38 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.38 |
| ▸ | STK10 | O94804 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | YES1 | P07947 | 1/20 | 0.38 |
| ▸ | LYN | P07948 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3156201 | 0.88 | KDR (0.42) | PDPK1KDRBDKRB1RAF1LCK | |
| SCHEMBL4973733 | 0.81 | DHPS (0.52) | PDPK1METKDRRET | |
| SCHEMBL6103207 | 0.81 | PDPK1 (0.52) | PDPK1KDRBDKRB1FLT3CIT | |
| SCHEMBL3156156 | 0.80 | KDR (0.46) | KDRBDKRB1FLT3CITMAP3K7 | |
| SCHEMBL3145678 | 0.80 | KDR (0.47) | KDRBDKRB1FLT3CITMAP3K7 | |
| SCHEMBL3155139 | 0.80 | KIT (0.48) | KDRBDKRB1FLT3CITMAP3K7 | |
| SCHEMBL3151422 | 0.80 | BDKRB1 (0.43) | PDPK1KDRBDKRB1FLT3CIT | |
| SCHEMBL3150762 | 0.79 | BDKRB1 (0.45) | PDPK1KDRBDKRB1FLT3CIT | |
| SCHEMBL4977326 | 0.79 | MET (0.49) | PDPK1METKDRFLT3CIT | |
| SCHEMBL4967228 | 0.77 | CCNA2 (0.40) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971604-B1 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | AMGEN INC (US) | 2012-08-01 | — | — | EP | claimed |
| EP-1971604-A2 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | Amgen Inc. (US) | 2008-09-24 | — | — | EP | claimed |
| US-20070185171-A1 | Compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | claimed |
| WO-2007048070-A2 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | AMGEN INC. (US) | 2007-04-26 | — | — | WO | claimed |
| US-8247556-B2 | Method for preparing 6-substituted-7-aza-indoles | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247556-B2 | Method for preparing 6-substituted-7-aza-indoles | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247556-B2 | Method for preparing 6-substituted-7-aza-indoles | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| EP-1971604-B1 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | AMGEN INC (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-1971604-A2 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | Amgen Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070185171-A1 | Compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070185171-A1 | Compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070185171-A1 | Compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007048070-A2 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | AMGEN INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185171-A1 | Compounds and methods of use | VHL, PGF, PTGIS | PDPK1 1891/4885MET 994/4885KDR 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.